FDA expands Sprycel approval to include certain children with acute lymphoblastic leukemia
The FDA expanded the approval of dasatinib tablets to include its use with chemotherapy for children aged 1 year or older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.